Ostial Corporation Reaches 15,000 FLASH™ System Units Sold

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

Irrimax Receives FDA Clearance for Irrisept

"This new clearance from the FDA further solidifies Irrisept as the market leader in wound irrigation," said Mark Alvarez, CEO of Irrimax.

Ostial Corporation (Ostial), is a private medical technology company focused on addressing the clinical challenges of aorto-ostial interventions.  Today the company announced they have reached a new milestone, passing the mark of 15,000 commercial units sold of its FLASH™ Aorto-Ostial Angioplasty System (FLASH System) in over 300 hospitals across the United States. FLASH is the first and only dual balloon-based system designed for use in aorto-ostial angioplasty in coronary and peripheral cases.

“Aorto-ostial lesions are notoriously difficult vascular interventions due to their challenging location and complex vessel morphology,” stated William Lombardi, MD, Clinical Professor of Medicine, Director of Complex Coronary Artery Disease Therapies and Attending Physician at the University of Washington Medical Center in Seattle, Washington. “FLASH is an optimal treatment for these high-risk lesions as it allows me to confidently treat the entire diseased area, while maintaining access for future interventions.”

The FLASH System is an innovative dual-balloon angioplasty catheter designed to help overcome challenges of aorto-ostial stenting by delivering true 360° stent apposition at the ostium. The novel technology employs a non-compliant distal balloon that post-dilates and anchors the system while an outer compliant contouring proximal balloon allows the operator to precisely position the catheter at the aorto-ostium, gently flaring the stent to the ostium wall. Total stent apposition with FLASH optimizes patient outcomes while improving reaccess for future interventions.1

“This is a significant achievement for our company, and I would like to thank our small yet growing team for reaching this important milestone,” stated Jon Bohane, General Manager and Chief Operating Officer of Ostial Corporation. “We are pleased to offer physicians and their patients the only aorto-ostial balloon that achieves complete and efficient lesion coverage.”

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles